Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

被引：0
|
作者：
S J Isakoff
D Wang
M Campone
A Calles
E Leip
K Turnbull
N Bardy-Bouxin
L Duvillié
E Calvo
机构：
[1] Massachusetts General Hospital Cancer Center,Division of Hematology and Oncology
[2] and Harvard Medical School,undefined
[3] Phase I Clinical Trials Program,undefined
[4] Henry Ford Hospital,undefined
[5] 2799 West Grand Boulevard,undefined
[6] Institut de Cancerologie de l'Quest—Rene Gauducheau,undefined
[7] Saint Herblain,undefined
[8] START Madrid,undefined
[9] Centro Integral Oncológico Clara Campal,undefined
[10] Hospital Madrid Norte-Sanchinarro,undefined
[11] Oncology Clinical Statistics,undefined
[12] Pfizer Inc,undefined
[13] Oncology Clinical Development,undefined
[14] Pfizer Inc,undefined
[15] 10 Fawcett Street,undefined
[16] Suite 2013,undefined
[17] Oncology Late Phase Strategy Development,undefined
[18] Pfizer Global Research and Development,undefined
[19] Oncology Clinical Development,undefined
[20] Pfizer Global Research and Development,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
bosutinib; capecitabine; neoplasms; metastatic cancer; phase 1; safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2058 / 2066
页数：8
相关论文
共 50 条
  • [41] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [42] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    S Lheureux
    A M Oza
    S A Laurie
    R Halford
    D Jonker
    E Chen
    D Keller
    V Bourade
    L Wang
    L Doyle
    L L Siu
    R Goel
    British Journal of Cancer, 2015, 113 : 1534 - 1540
  • [43] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    Lheureux, S.
    Oza, A. M.
    Laurie, S. A.
    Halford, R.
    Jonker, D.
    Chen, E.
    Keller, D.
    Bourade, V.
    Wang, L.
    Doyle, L.
    Siu, L. L.
    Goel, R.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1534 - 1540
  • [44] Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
    Heery, Christopher R.
    O'Sullivan-Coyne, Geraldine
    Madan, Ravi A.
    Cordes, Lisa
    Rajan, Arun
    Rauckhorst, Myrna
    Lamping, Elizabeth
    Oyelakin, Israel
    Marte, Jennifer L.
    Lepone, Lauren M.
    Donahue, Renee N.
    Grenga, Italia
    Cuillerot, Jean-Marie
    Neuteboom, Berend
    von Heydebreck, Anja
    Chin, Kevin
    Schlom, Jeffrey
    Gulley, James L.
    LANCET ONCOLOGY, 2017, 18 (05): : 587 - 598
  • [45] Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors
    Awada, A.
    Gil, T.
    Whenham, N.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Loembe, B.
    Piccart, M.
    Hendlisz, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
  • [46] Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors.
    Tsai, Hui-Jen
    Chiang, Nai-Jung
    Shiah, Her-Shyong
    Chang, Kwang-Yu
    Su, Wu-Chou
    Chang, Jang-Yang
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [47] Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
    Schuler, Martin
    Cho, Byoung Chuf
    Sayehli, Cyrus Michael
    Navarro, Alejandro
    Soo, Ross A.
    Richly, Heike
    Cassier, Philippe Alexandre
    Tai, David
    Penel, Nicolas
    Nagoya, Lucia
    Park, Se Hoon
    Schostak, Martin
    Gajate, Pablo
    Cathomas, Richard
    Rajagopalan, Prabhu
    Grevel, Joachim
    Bender, Sebastian
    Boix, Oliver
    Nogai, Hendrik
    Ocker, Matthias
    Eflinghaus, Peter
    Joerger, Markus
    LANCET ONCOLOGY, 2019, 20 (10): : 1454 - 1466
  • [48] Phase I dose escalation, pharmacokinetic, and biomarker study of imatinib mesylate plus capecitabine in advanced solid tumor malignancies.
    Favaro, J. P.
    Petros, W.
    Hong, T.
    Fernando, N.
    Bendell, J. C.
    Gockerman, J. P.
    George, D. J.
    Williams-Truax, R.
    Nixon, A.
    Yu, D.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 144S - 144S
  • [49] Phase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part
    Yamamoto, N.
    Sato, J.
    Koyama, T.
    Iwasa, S.
    Shimomura, A.
    Kondo, S.
    Kitano, S.
    Yonemori, K.
    Fujiwara, Y.
    Tamura, K.
    Suzuki, T.
    Takase, T.
    Nishiwaki, Y.
    Nakai, K.
    Shimizu, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study
    Blais, Normand
    Camidge, D. Ross
    Jonker, Derek J.
    Soulieres, Denis
    Laurie, Scott A.
    Diab, Sami G.
    Ruiz-Garcia, Ana
    Thall, Aron
    Zhang, Ke
    Chao, Richard C.
    Chow, Laura Q.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1487 - 1498
12345